All In Biotech

Drug Trial Radar · NCT06408727

Intermediate Expanded Access Protocol CNMAu8.EAP04

An Intermediate Expanded Access Protocol With CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012

Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Temporarily not available

Status

Temporarily not available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Clene NanomedicineIndustry
Sponsor type
Industry
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
May 10, 2024

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012

Conditions

  • ALS
  • Amyotrophic Lateral Sclerosis
  • PALS

Interventions

  • CNM-Au8Drug

    CNM-Au8 (cellular energetic nanocatalyst). Faceted clean-surfaced catalytically-active Au nanocrystals.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Nova Southeastern University

    Fort Lauderdale, Florida

  • Northwestern University

    Chicago, Illinois

  • Synapticure

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Columbia Unniversity

    New York, New York

  • Duke University

    Durham, North Carolina

  • Pennsylvania State University

    Hershey, Pennsylvania

  • Texas Neurology

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.